The role of insulin-like growth factor 1 receptor in thyroid associated ophthalmopathy
The pathogenic mechanisms of thyroid-associated ophthalmopathy(TAO)have not been fully elucidated.Overexpression of insulin-like growth factor 1 receptor(IGF-1R)plays a certain promoting role in the pathogenesis of TAO,and the use of its inhibitor,teprotumumab,can exert an inhibitory effect on the clinical manifestations and progression of TAO.Elevated levels of immunoglobulin G and beta-blocking protein in the serum of TAO patients can regulate the expression or function of IGF-1R,promoting the clini-cal manifestations and progression of TAO.In 2020,teprotumumab became the first drug approved by the U.S.FDA for the treatment of TAO,and the implementation of targeted anti-IGF-1R therapy and related clini-cal trials have laid the foundation for studying the role of IGF-1R in the pathogenesis of TAO and targeted therapy for TAO.(Int Rev Ophthalmol,2024,48:139-144)
NETL
NSTL
万方数据
